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Ovarian cancer (OC) is the fifth leading cause of cancer deaths among women, 
thus early diagnosis is of paramount importance to survival. A clear OC etiopatho-
genesis is not yet fully understood. Large histopathological variability predicts more 
initial tissue for carcinogenesis. Many connections of biologically different tissue 
as locus minoris resistentiae for carcinogenesis have been confirmed. Expansion of 
knowledge about OC etiopathogenesis may help to construct an algorithm for early 
diagnosis. Ovarian surface epithelium, ectopic Müllerian epithelium, and fallopian 
tubes, along with endometriosis, are significant in the process of OC development. 
An oxidative microenvironment caused by recurrent ovulation or arising due to 
a degradative process in ectopic endometrium, mainly endometriomas, play a 
prominent role in the development of OC.
Keywords: ovarian cancer, etiopathogenesis, ovarian surface epithelium, cortical 
inclusion cyst, fallopian tube, endometriosis, endosalpingiosis, ovulation,  
tubo-ovarian junction, ovarian carcinogenesis
1. Introduction
Although ovarian cancer (OC) is not the most common cancer, it is the fifth 
leading cause of cancer deaths among women [1] and accounts for 3–4% of all 
female cancers. Improvement of therapeutic options in OC patients has improved 
disease-free survival but has had no significant effect on overall survival. There 
is still the need for genetic profiling to identify patients who will benefit from 
anti-angiogenic treatment [2, 3]. Due to the typical disease characteristics, such 
as initially asymptomatic growth and delayed symptoms, most OC patients are 
diagnosed at an advanced stage. Early diagnosis at the asymptomatic stage is of 
paramount importance for survival. Understanding OC development pathways 
can help with early diagnosis and thus increase the potential of curability as well as 
screening programs.
2. Ovarian cancer - background
2.1 Classification
Histo-anatomy and tumour biology are main determining factors in OC 
classification.
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Up to 90% of all OC is derived from the epithelium. The remaining 10% 
represents non-epithelial cancers with sex-cord stromal tumours and germ cell 
tumours. Epithelial OC is either mucinous (3%) or non-mucinous (97%). The 
most represented group, non-mucinous, includes serous OC, endometrioid ovar-
ian cancer (EOC), clear cell ovarian cancer (CCOC), transitional cell carcinoma, 
and others.
The model of two different tumour types in epithelial OC is widely supported 
and was officially accepted by the World Health Organisation (WHO) in 2004 [4]. 
Type 1 OC is defined from precursor through borderline variants. These cancers 
usually have an indolent course and good prognosis. Type 2 OC, such as high-grade 
serous ovarian cancer (HGSOC), reports fast progression, aggressiveness, and 
poor prognosis (Figure 1). Ninety percent of all deaths from OC are caused by this 
type [5].
The most common secondary cancers are metastatic lesions in the gastrointestinal 
tract or breasts [6].
2.2 Carcinogenesis: basic orientation
The cells of origin for OC are well studied, although some OC may not originate 
in the ovaries. OC in extra-ovarian tissue can also occur. For example, mucinous OC 
can resemble other endocervical glands and gastro-intestinal epithelium.
EOC and CCOC often show the presence of endometriosis in their histology. 
Histopathological criteria can clearly define a couple of types of endometriosis with 
different biological potential. While benign endometriosis faces the onset of the 
endometriosis overthrow, atypical endometriosis is already an ongoing process. The 
range as well as the time interval of oxidative load significantly affect which deposit 
of benign endometriosis progresses. The degradation processes typically seen in 
ectopic endometrium are the source of oxidative stress, and close contact with the 
Figure 1. 
Ovarian cancer classification due to histo-anatomy and tumour biology with possible initial source.
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ovary potentiates this process. This explains why ovarian endometriomas have the 
greatest potential for progression and why there is less risk of progression in deep 
infiltrating endometriosis.
Serous OC can originate in the ovary as well as extra-ovarian tissue. The close 
relationship was observed with fallopian tube, mainly its fimbriated end. Fallopian 
tube epithelium (FTE) plays an important role in the development of ovarian 
malignancy. The precursor originating from the FTE can locally progress or, more 
often, adhere to the more favourable environment of the ovary. Local progression 
of the precursor derived from the FTE is rare. The reason for this is the inhibitory 
effect of the fallopian tube microenvironment on carcinogenesis when compared 
to the ovarian microenvironment. Oxidative stress resulting from incessant ovula-
tion leads to accumulation of DNA changes in the FTE with subsequent exfoliation 
of precursors to the ovarian surface epithelium. Even more tissues for ovarian 
carcinogenesis with different biological potential have been recognised in the FTE. 
Type 1 OC, although containing oncogene alterations of RAS-PMK or PI3K-AKT, is 
genomically stable, for example, as in wild-type p53. Type 2 OC reports p53 muta-
tions and pronounced genomic instability [5].
Generally, the initial tissue for OC development can be located in the ovary, 
ectopic Müllerian epithelium, fallopian tube, or endometrium (Figure 1).
Age older than 64 years is a risk factor for OC mortality and risk of disease 
increases significantly with advancing age. Within a genetic predisposition only 
limited clinically relevant mutations are currently known. Knowledge about 
tumour suppressor genes, BRCA mutations, and Lynch syndrome help to construct 
a preventive surgery programme for patients. An oxidative microenvironment due 
to incessant ovulation in the tubo-ovarian junction or degradative processes in 
endometriomas are considerable risk factors for DNA alterations. Thus, decreased 
ovulation may act as a protective factor against OC, although not every situation 
Group of factors Factor + — +/−
Age Age •
Genetic Family history •
BRCA mutation •
Lynch syndrome •





Hormonal Hormonal contraceptives •
Hormone replacement therapy •
Gynaecological Endometriosis •
Pelvic inflammatory disease •




The share of individual factors in protection (+), predisposition (−) or controversial position (+/−) in relation 
to the OC development.
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confirms this fact (Table 1). The main factors influencing risk-reduction strategies 
are genetic predispositions, ageing, and parity.
3. Ovarian cancer: etiopathogenesis
3.1 Ovary
The infiltration of the ovaries by cancer cells even in the early stages of OC has 
been confirmed. Due to this fact, the initial concept was that the origin of OC is in 
the ovary. The ovarian surface epithelium (OSE) covers the ovary and during ovula-
tion invagination of the OSE may occur, leading to the formation of small cystic 
lesions located in the ovarian cortex called cortical inclusion cysts (CICs).
The engagement of ovulation in carcinogenesis has been known for about 
50 years. The oxidative stress accompanying ovulation alters the cells of the OSE. 
The accumulation of DNA damages arising due to the pro-inflammatory and pro-
oxidative microenvironment and subsequent inability to repair them leads to the 
formation of pathological clone cells (Figure 2). In addition, women with a BRCA 
mutation and decreased ability of DNA repair are more prone to this process [7].
Incorporated CICs containing DNA-altered cells, as well as ambient pluripotent 
stem cells, are exposed to cyclic inflammatory activity. It has already been described 
that stem cell activity is silenced in cancerous OSE [8]. Thus, dysregulated pluripo-
tency of stem cells may contribute to growth promotion and differentiation, finally 
leading to cancer formation [7]. Inadequate host tissue stem cell activity as the 
factor potentiating growth and malignant transformation in other cancers such as 
colorectal carcinoma has also been described [9].
The histology of certain HGSOC shows similarity to tissue developmentally 
derived from Müllerian ducts (Figure 3). One possible reason for this is that the 
relatively unstable, undifferentiated nature of OSE may mould the tissue of a 
Müllerian phenotype through the process of metaplasia [10]. Metaplastic OSE with 
different phenotype create after its incorporation into CIC Müllerian type of corti-
cal inclusion cyst (mCIC), finally progressing into OC. This represents a theory of 
OC development from Müllerian epithelium but initially arising from metaplastic 
OSE. Another theory is the transport of Müllerian epithelium into the OSE from 
extra-ovarian localisation (e.g., ectopic Müllerian epithelium, endosalpingiosis, or 
fallopian tubes).
3.2 Ectopic Müllerian epithelium
As early as 1999, the theory that all epithelial OC originated initially from the 
ovary was challenged. As a primary source was indicated extra-ovarian müllerian 
epithelium (Figure 3). It was observed that Müllerian epithelium has more similar 
patterns to HGSOC than to OSE. The theory was supported by proof of the absence 
of ovarian tissues in primary peritoneal cancers without ovarian invasion but 
that were clinically and histopathologically consistent with HGSOC. Secondary 
Müllerian tissue as the residue of ectopic Müllerian epithelium (outside of the 
cervix, endometrium, or fallopian tubes) as the source of cells for carcinogenesis 
has been confirmed [11].
3.2.1 Endosalpingiosis
Endosalpingiosis (ES) represents an ectopic presence of FTE. When compared 
to endometriosis, ES shows ciliary epithelium and absence of inflammatory 
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reaction. In addition, there is a difference in incidence related to age among these 
two conditions. The discovery of fallopian tube importance in the process of ovar-
ian carcinogenesis and subsequent implementation of sectioning and extensively 
examining the fimbriated end protocol (SEE-FIM) led to increased ES rates. In 
women aged 31–50 years, ES incidence is 37%. In menopausal women, incidence 
increases to 66% [12]. Endometriosis incidence rapidly decreases after menopause, 
whereas an opposite effect is seen in ES. This is caused by the different biology of 
the diseases, although both entities probably arise from dissemination of physi-
ologically localised tissue. While endometriosis represents a hormone-dependent 
disease, ES probably arises from tissue detachment of FTE. Due to the hormonal 
attenuation after menopause, endometriosis regresses; however, increasing age 
increases the probability of exfoliation of FTE from fallopian tubes. Different 
biological potential can also be present. In ES tissues degradative processes are miss-
ing, which means less oxidative load. Thus also malignant potential of ES should be 
present when compare to endometriosis.
The theories of ES development discuss two possibilities. One envisages a meta-
plasia of pluripotent coelomic peritoneal epithelium to FTE tissue. More likely it is a 
process of primary dissemination of FTE. This second theory explains the presence 
of ES in women only and that the most common localization of ES is in the ovaries.
Figure 2. 
Cortical inclusion cyst formation from ovarian surface epithelium under the effect of oxidative stress resulting 
from ovulation.
Figure 3. 
The development of female genitals and role of Müllerian ducts.
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Relevant clinical data about ES are scarce, although recent studies show its asso-
ciation with gynaecological malignancies [13]. A significant relationship between 
ES and borderline ovarian carcinoma (BOC) has been observed. One third of serous 
BOC patients present with ES in their histology and incidence of ES increases to 
70% in recurrent serous BOC [14]. The connection with slowly progressing cancers 
is likely due to low biological activity of ES.
3.3 Fallopian tube
In 2001, small dysplastic lesions similar to HGSOC containing BRCA mutations 
were discovered in a patient’s fallopian tubes [15]. Serous tubal intraepithelial 
carcinoma (STIC) is characterised by enlarged epithelial cells with atypia of 
nucleoli. The distal part of the fallopian tube is the main region where STIC is seen. 
This is most probably due to the close connection with the ovary where ovula-
tion with chronic inflammatory and oxidative microenvironment takes place. 
Immunohistochemical study of STIC showed positivity of p53 as well as γH2AX, 
which is a marker of double-stranded DNA breaks [16].
The presence of STIC and HGSOC at the same time was confirmed in 11–61%. 
The incidence of STIC in asymptomatic risky patients after prophylactic adnex-
ectomy was reported to be 0.4%–8.5%. The incidence in risk-free patients was 
0.8%–3.1% [17]. Relatively wide incidence of STIC in HGSOC patients is due to 
non-identical diagnostic criteria of STIC. The criteria for STIC diagnosis are:
• morphological abnormalities including change of nucleus/cytoplasm ratio, 
enlarged nucleus with prominent nucleoli, ciliary cells reduction, and absence 
of basement membrane penetration
• p53 overexpression (> 60%) or absence of expression
• increased proliferative index Ki67 (> 10% positive cells in lesion)
The knowledge of early tubal precursors increased a request for precise fallopian 
tubes assessment. On the other hand implementation of detailed investigation pro-
tocol uncovered more microscopic lesions with not known tasks. Apart from STIC, 
three other lesions need to be taken into consideration: p53 signature, secretory cell 
outgrowth (SCOUT), and serous intraepithelial lesion (STIL).
p53 signature represents a cluster of FTE reporting p53 positivity with  
Ki67 ˂ 10%. Morphological changes are not present and therefore a diagnostic 
process is focused on immunohistochemical examination. It can be a bilateral 
and multifocal lesion; the role is not fully clarified. It can be an initial step with 
subsequent progression or the lesion can persist.
SCOUT is defined as a proliferation of at least 30 secretory fallopian tube cells 
with Bcl2 positivity as well as P53 negativity. Another feature is loss of PAX2, 
which is seen in STIC as well as in HGSOC. This predicts PAX2 inactivity as part 
of carcinogenesis and SCOUT can be a step of this process. The amount of SCOUT 
increases with age and most likely represents a precursor of p53 lesions [18]. 
However, they are not reported in clinical findings due to their unclear clinical 
importance.
STIL contains atypia but does not reach STIC. It represents a morphological 
intermediate stage between p53 and STIC [18].
The process of ovarian carcinogenesis starting in the FTE under the effect of 
ovulation takes more than 30 years. Development of p53 signature from secretory 
epithelial cells of the fallopian tubes lasts approximately 10 years, and it takes 
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another 15 years for the development of STIC, and then 5 more years for the devel-
opment of HGSOC from STIC (Figure 4) [19].
The knowledge of FTE hypothesis as the source of OC potentiates an idea of 
reduction of preventive surgery range in high-risk patients. Due to the lack of 
information about the role of fallopian tubes on general OC incidence, the risk 
reduction of OC occurrence after prophylactic salpingectomy cannot be established. 
The omission of oophorectomy in premenopausal women prevents menopausal side 
effects but certain risk of OC remains.
3.3.1 STIC transport to ovaries
Although the STIC as a precursor of HGSOC is clearly defined, infiltration 
of the fallopian tubes was not observed in a large proportion of patients with 
HGSOC [20]. The reason for this is the theory of transportation of early genomi-
cally altered secretory epithelial cells from the distal part of fallopian tubes into 
the OSE. Implantation of tissue in the CIC of OSE leads to formation of mCIC 
(Figure 5) where the ovarian microenvironment creates better conditions for 
cancer progression [21].
The question of whether OC originates in the ovary or the fallopian tube is not 
fully answered. The microenvironment plays a crucial role. Whereas the ovary 
accelerates the process of cancer initiation, progression, and growth, the fallopian 
tubes more likely have an inhibitory effect [21]. This may explain why the precur-
sor in case of cancer originating from the ovary cannot be detected. The process 
in these cancers is so rapid that precancerous lesions are often not detected. 
Inversely, in the fallopian tubes there is a longer time window for detecting early 
lesions, and after their transportation into the ovary the acceleration of the cancer 
is seen.
Although the conditions for progression are apparently better in the ovaries, 
local progression of STIC in the fallopian tubes and formation of primary fallopian 
tube carcinoma can occur.
Figure 4. 
The biological course of ovarian carcinogenesis starting in fallopian tube epithelium.
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3.3.2 Papillary tubal hyperplasia
The fallopian tubes play a role in some type 1 cancers. Papillary tubal hyperpla-
sia (PTH) represents a cluster of epithelial cells and small papillae with or without 
psammomatous bodies in the lumen of the fallopian tube (Figure 6). They float 
freely in tubal lumen or protrude from the epithelium into the lumen. This is a 
crucial difference from tubal hyperplasia. It was suggested that PTH represents 
the most advanced stage of tubal hyperplasia and has a significant association with 
some ovarian and extra-ovarian low-grade tumours. Earlier stages of tubal hyper-
plasia do not show such a prominent association [22].
PTH arises as the consequence of chronic inflammatory processes and can be 
diffuse or focal. Anatomically the most common place of appearance is the tubal 
ampoule. After its transport into the ovary, PTH can progress and form serous BOC 
and subsequently low-grade serous ovarian cancer (LGSOC). Many morphologi-
cal similarities of PTH and LGSOC have been confirmed. Both contain ciliary 
and secretory cells as well as intraepithelial lymphocytes. Psammomatous bodies 
commonly present in PTH as well as LGSOC. After its transportation on peritoneal 
surfaces, PTH represents a precursor of ES or non-invasive implants.
Chronic inflammatory changes (i.e., chronic salpingitis or other forms of pelvic 
inflammatory disease) leading to architectural reconstruction of the fallopian 
tube induce FTE proliferation resulting in PTH. Mutation of KRAS or BRAF 
genes represent the main trigger of carcinogenesis. After its transportation into 
the ovary, the final structure is usually mCIC. Not all studies have confirmed this 
algorithm and significant association of PTH with LGSOC or serous BOC was not 
seen [23, 24]. More studies in this area are still needed.
3.3.3 Primary fallopian tube carcinoma
Primary fallopian tube carcinoma (PFTC) represents a rare entity accounting 
for 0.14%–1.8% of all female genital tract cancers. Nevertheless, the incidence in 
the last several years has increased due to the change in fallopian tube assessment. 
Wide implementation of the SEE-FIM protocol into clinical practice increased 
detection of different precursors from FTE as well as the incidence of PFTC. 
Unfortunately, they represent mainly asymptomatic lesions or, like in some PFTC 
cases, are indicated for surgery due to adnexal mass. At present, PFTC is considered 
to be the presence of STIC or invasion of the carcinoma into the fallopian tube 
mucosa or if the fallopian tube is incorporated into the tumour mass [25].
The precursor in HGSOC or high-grade serous extra-ovarian cancer is STIC 
with a typical p53 mutation. In case of HGSOC or extra-ovarian cancer, STIC is 
Figure 5. 
The process of incorporation of fallopian tube cells into ovarian surface epithelium.
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detached from the FTE and implanted on surfaces without invasion of tissue under 
the basement membrane of the FTE. However, in case of PFTC a local progression 
of STIC with invasion into deeper structures is seen. Localisation of PFTC in the 
tubal lumen leads to its distension with earlier clinical symptoms. Therefore, PFTC 
diagnosis is done earlier than that for HGSOC. In addition, the partially closed 
space of tubal lumen can delay spread of disease in the abdominal cavity.
3.4 Endometriosis
Endometriosis is a clinically complex syndrome with chronic hormone-dependent 
inflammation and notable proliferative potential. Although endometriosis incidence 
is around 10%, it accounts for less than 1% of malignancies [26].
The common features of endometriosis and cancer cells have been clearly 
described. These include angiogenic potential of stem cells as well as their ability 
to evade apoptosis. Haemolysis, the process typical for endometriosis, is highly 
associated with oxidation. An oxidative microenvironment results in accumulation 
of DNA mutations and leads to, under the supervision of the immune system, either 
cell death or formation of pathogenic clone cells.
The similar effect like in FTE, which is for better conditions of malignization 
transported into ovary is also in endometriosis seen. Inflamed stroma with mutated 
epithelium can progress to cancer when located on the ovary. This explains why 
malignant overthrow is uncommon in the case of deep infiltrating endometriosis 
even when containing similar DNA mutations [26]. The microenvironment plays an 
important role in these situations as well.
Endometriosis-associated ovarian cancer (EAOC) includes mainly endometri-
oid ovarian cancer (EOC), clear cell ovarian cancer (CCOC), and sero-mucinous 
borderline ovarian cancer. Nevertheless, not every case of EAOC presents with 
endometriosis. EAOCs are characterised as well-differentiated tumours occurring at 
a younger age and initially diagnosed at an earlier stage when compared to endome-
triosis-free EAOC. The question which endometriotic lesion tend to progress into 
carcinoma remains still not completely answered.
Figure 6. 
Papillary tubal hyperplasia. Numerous small papillae/thin arrows/psamomatous bodies/gross arrows/.
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Benign and atypical (premalignant) endometriosis can be defined using his-
topathological criteria. There is a significant association of atypical endometriosis 
(AE) with EAOC. While benign endometriosis (BE) does not contain atypia and has 
greater incidence, AE is less frequently seen and the atypia can be defined in two 
grades [27]. Cellular atypia, also called cytological atypia, defines epithelial layer 
changes such as hyperchromasia and pleomorphism. However, structural atypia, 
also called hyperplasia, deputises hyperplastic changes similar to ectopic endome-
trium, which includes simple or complex hyperplasia with or without cellular atypia 
[28]. Although plenty of studies refer to AE as tissue with cytological and structural 
atypia, cytological atypia are seen in cancer-free patients, whereas structural atypia 
are typically present in OC patients (Figure 7) [27].
The different potential of both types of atypia have been confirmed by studies 
of COX-2, Ki-67, and BAF250a. In the case of BE, immunohistochemical COX-2 
positivity is significantly higher compared to that in AE. In both types of atypia 
in AE, rapidly higher COX-2 positivity in cytological atypia has been observed. 
This predicts BE as well as cytological atypia of AE into reactive changes. In Ki-67 
examinations lower values in BE and cytological atypia of AE were detected. Thus, 
the structural atypia of AE can be concluded as the tissue with greater proliferative 
potential. The decrease in BAF250a was confirmed in both OC and AE patients. 
Comparing both types of atypia in AE, we can see lower BAF250a expressions in 
structural atypia patients [27].
EAOC tissue can be present with or without endometriosis. If endometriosis is 
confirmed, both types can be seen (BE as well as AE). In some cases even gradual 
transition from BE to AE and BOC can be detected. Approximately one of 10 
women suffers from endometriosis and only less than 1% (0.3%–0.8%) of endome-
triosis patients will progress to cancer. When checked for AE incidence in endome-
triosis patients, 8% show atypia in their histology. The incidence of AE increases 
in patients with OC, whereas one-third of EAOC patients present with AE [27]. 
Detailed analysis of AE patients showed those with long-term history of disease, 
advanced stage, and older age when compared to BE patients. Current accepted 
criteria for AE include eosinophilic cytoplasm, large hyperchromatin or pale nuclei 
with moderate-to-marked pleomorphism, increased nucleus-to-cytoplasm ratio, 
and cell aggregation.
The endometriosis was solidly confirmed as the precursor of some OC, pref-
erentially of certain portion of EAOC. Due to the low incidence of endometriosis 
Figure 7. 
The development of changes in ectopic endometrium.
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overthrow, predictive factors are not fully clarified. There is significantly greater 
association of endometriomas with malignancy when compared to deep infiltrating 
endometriosis. In those cases, the ovarian microenvironment plays a crucial role. 
Thus, even in endometriosis overthrow a tubo-ovarian junction is inevitably needed 
to ensure endometrial reflux to the ovary and then cellular progression in the 
endometrioma. From the clinical characteristics of OC, patients with long-term his-
tory of disease as well as large endometriomas (> 9 cm) may be defined as high-risk 
patients for progression and thus require more precise observation (Table 2) [29].
4. Conclusion
Incidence of OC is relatively low when compared to other onco-gynaecological 
diseases. Nevertheless, OC is the fifth leading cause of cancer deaths among women 
with 95% of deaths occurring in women older than 45 years.
Disease localisation in the abdominal cavity allows asymptomatic growth at 
the early stages. The diagnostic timing of symptomatic disease does not affect the 
parameters of survival. To increase survival rate, it is important to detect the disease 
at the early asymptomatic stage. Knowledge of disease etiopathogenesis increases 
the probability of detecting precancerous lesions or early-stage cancers.
The source of OC can be OSE through CIC or mCIC. Local progression is seen 
less frequently, whereas transport of the precursor to the ovarian surface is more 
common. Retrograde menstruation may be a cause of some EAOCs, mainly EOC 
and CCOC.
Initial structure Biological process Final structure
OSE Mutation + incorporation into small cyst CIC
OSE Metaplasia + incorporation into small cyst mCIC
Ectopic Müllerian 
epithelium
Local progression transport to the ovary Primary peritoneal cancer 
mCIC
ES Transport to the ovary Serous BOC
FTE Transport to the ovary mCIC
STIC Local progression PFTC
STIC Transport to the ovary HGSOC
PTH Transport to the ovary BOC/LGSOC




Simplified process of ovarian carcinogenesis.
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